Skip to main content

Table 1 Baseline characteristics of patients

From: Danaparoid sodium-based anticoagulation therapy for portal vein thrombosis in cirrhosis patients

 

n = 52

Sex (male / female)

40/12

Mean age (years)

65 ± 9

Etiology (HBV / HCV / HBV + HCV / NBNC)

7/29/1/15

Child-Pugh score (A / B / C)

13/25/14

Hepatocellular carcinoma (absent / present)

31/21

UICC Stage of hepatocellular carcinoma

 Absent (none / after curative treatment)

19/12

 Present (Stage I / II / III / IV)

8/12/0/1

Esophageal varices (absent / present)

1/51

Monotherapy / Combination therapy

30/22

White blood cell count (/μL)

3773 ± 1994

Hemoglobin (g/dL)

11.2 ± 1.8

Platelet count (× 104/μL)

9.0 ± 6.4

Albumin (mg/dL)

3.1 ± 0.5

Total bilirubin (mg/dL)

1.6 ± 1.1

Aspartate aminotransferase (IU/L)

46 ± 24

Alanine aminotransferase (IU/L)

32 ± 19

Gamma-glutamyl transpeptidase (IU/L)

47 ± 59

Prothrombin time (%)

64 ± 14

Prothrombin time/International normalized ratio

1.3 ± 0.2

Fibrinogen degradation product (μg/mL)

15.7 ± 17.1

D-dimer (μg/mL)

7.5 ± 8.1

Antithrombin III (%)

58 ± 17